Profile data is unavailable for this security.
About the company
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.
- Revenue in AUD (TTM)3.90m
- Net income in AUD-12.13m
- Incorporated2015
- Employees1.00k
- LocationNoxopharm LtdSuite 71, 159 Ridgecrop DriveCASTLE HILL 2154AustraliaAUS
- Phone+61 29144-2223
- Fax+61 29199-9600
- Websitehttps://www.noxopharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncosil Medical Ltd | 355.30k | -11.71m | 16.66m | 2.00 | -- | 2.56 | -- | 46.89 | -0.0081 | -0.0081 | 0.0002 | 0.002 | 0.0506 | -- | 7.88 | -- | -166.55 | -57.65 | -234.81 | -64.83 | -426.96 | -- | -3,295.08 | -473.02 | -- | -68.93 | 0.0256 | -- | -59.92 | -37.72 | -5.74 | -- | 40.13 | -- |
| Auscann Group Holdings Ltd | 2.05m | -9.44m | 17.61m | 27.00 | -- | -- | -- | 8.60 | -0.0213 | -0.0217 | 0.0043 | 0.0162 | 0.1674 | -- | 5.35 | -- | -77.15 | -39.85 | -78.72 | -40.73 | 100.59 | -- | -460.74 | -925.91 | -- | -23.16 | 0.00 | -- | 13.88 | 51.37 | 57.10 | -- | -- | -- |
| Rhythm Biosciences Ltd | 157.67k | -8.63m | 17.65m | -- | -- | 12.90 | -- | 111.95 | -0.0386 | -0.0386 | 0.0007 | 0.0055 | 0.0263 | -- | 1.81 | -- | -144.00 | -106.11 | -169.71 | -125.51 | -1,899.74 | -1,210.71 | -5,473.20 | -6,642.26 | 2.04 | -- | 0.0304 | -- | 814.18 | 28.77 | 6.55 | -- | -20.43 | -- |
| Lumos Diagnostics Holdings Ltd | 12.28m | -13.19m | 17.81m | -- | -- | 1.29 | -- | 1.45 | -0.0354 | -0.0354 | 0.0349 | 0.0287 | 0.3418 | 2.24 | 6.37 | -- | -36.70 | -40.15 | -55.14 | -56.67 | 59.73 | 45.97 | -107.38 | -162.90 | 0.479 | -6.25 | 0.4803 | -- | -9.42 | 39.29 | 80.38 | -- | -38.50 | -- |
| Algorae Pharmaceuticals Ltd | 84.10k | -2.25m | 18.56m | -- | -- | 5.12 | -- | 220.71 | -0.0015 | -0.0015 | 0.00006 | 0.0022 | 0.0245 | -- | 1.79 | -- | -65.51 | -46.12 | -70.91 | -53.52 | -- | -- | -2,678.04 | -591.05 | -- | -136.75 | 0.00 | -- | 1,132.26 | -44.06 | -7.68 | -- | -- | -- |
| LBT Innovations Limited | 2.00m | -21.38m | 18.77m | 17.00 | -- | 6.91 | -- | 9.37 | -0.0428 | -0.0428 | 0.0038 | 0.002 | 0.1087 | 0.0819 | 2.25 | 117,882.40 | -115.89 | -28.85 | -131.86 | -30.99 | 94.76 | -- | -1,066.62 | -441.76 | 3.30 | -6.85 | 0.5633 | -- | -5.29 | -18.45 | -239.17 | -- | -34.63 | -- |
| Amplia Therapeutics Ltd | 1.87m | -4.46m | 20.10m | 1.00 | -- | 1.00 | -- | 10.76 | -0.0224 | -0.0224 | 0.0094 | 0.0739 | 0.0949 | -- | 0.7018 | -- | -22.64 | -25.27 | -26.24 | -26.78 | -- | -- | -238.69 | -342.26 | -- | -- | 0.1318 | -- | -42.10 | 12.31 | -71.30 | -- | 31.88 | -- |
| Immuron Ltd | 3.58m | -3.88m | 20.52m | 6.00 | -- | 1.17 | -- | 5.74 | -0.017 | -0.017 | 0.0157 | 0.0769 | 0.1664 | 0.6468 | 7.92 | 596,106.70 | -18.06 | -27.48 | -19.86 | -29.58 | 80.87 | 77.52 | -108.52 | -296.64 | 7.79 | -2.85 | 0.0023 | -- | 135.85 | -13.34 | -32.66 | -- | 3.27 | -- |
| Cann Group Ltd | 16.45m | -29.28m | 21.87m | 40.00 | -- | 0.4306 | -- | 1.33 | -0.0724 | -0.0724 | 0.0406 | 0.1161 | 0.1237 | 0.3952 | 7.37 | -- | -22.03 | -22.28 | -34.23 | -24.43 | 21.11 | -- | -178.07 | -407.57 | 0.0861 | -5.88 | 0.5646 | -- | 114.90 | 89.76 | -27.66 | -- | -11.16 | -- |
| Acrux Ltd | 14.46m | -709.00k | 22.68m | 43.00 | -- | 4.01 | -- | 1.57 | -0.0024 | -0.0024 | 0.0502 | 0.0195 | 1.29 | -- | 4.86 | -- | -6.34 | -39.91 | -9.21 | -46.00 | 72.38 | -- | -4.90 | -132.53 | -- | -- | 0.2861 | -- | 133.74 | 28.29 | 92.23 | -- | -16.66 | -- |
| BPH Energy Ltd | 345.67k | 894.65k | 22.95m | 2.00k | 20.41 | 0.9868 | -- | 66.40 | 0.001 | 0.001 | 0.0004 | 0.0203 | 0.0177 | -- | 5.97 | -- | 4.58 | -6.89 | 4.78 | -7.72 | 56.39 | -- | 258.50 | -357.76 | -- | -- | 0.0043 | -- | 96.54 | 5.21 | 179.13 | -- | -- | -- |
| Noxopharm Ltd | 3.90m | -12.13m | 23.38m | 1.00k | -- | 3.56 | -- | 5.99 | -0.0415 | -0.0415 | 0.0134 | 0.0225 | 0.2684 | -- | 1.64 | 3,901.84 | -83.43 | -50.96 | -94.78 | -62.98 | -- | -- | -310.82 | -191.70 | -- | -1.47 | 0.00 | -- | 11.32 | 44.02 | 19.34 | -- | -- | -- |
| Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 25.05m | -- | -- | 3.72 | -- | 20.75 | -0.0162 | -0.0162 | 0.0037 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -66.34 | -120.26 | -79.70 | -- | -- | -357.70 | -228.11 | -- | -21.62 | 0.00 | -- | -18.97 | 138.73 | 29.29 | -- | 68.45 | -- |
| Alterity Therapeutics Ltd | 123.46k | -12.28m | 26.23m | 11.00 | -- | 0.7951 | -- | 212.42 | -0.005 | -0.005 | 0.00005 | 0.0063 | 0.0044 | -- | 1.52 | 11,223.64 | -44.20 | -53.02 | -53.57 | -61.96 | -- | -- | -9,947.97 | -40,995.62 | -- | -- | 0.0143 | -- | 557.60 | -39.40 | -7.47 | -- | -34.88 | -- |
| Syntara Ltd | 9.83m | -14.26m | 27.46m | 107.00 | -- | 3.05 | -- | 2.79 | -0.0197 | -0.0172 | 0.0136 | 0.0075 | 0.442 | 1.58 | 2.22 | -- | -64.13 | -27.33 | -97.76 | -34.23 | 81.69 | 88.37 | -145.11 | -61.99 | 1.75 | -262.59 | 0.0674 | -- | 23.60 | -18.30 | -486.78 | -- | -31.06 | -- |
Data as of Jun 07 2024. Currency figures normalised to Noxopharm Ltd's reporting currency: Australian Dollar AUD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DFA Australia Ltd.as of 31 May 2023 | 0.00 | 0.00% |
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
